HRG antibody (AA 412-511)

Catalog No. ABIN7155258

Product Details anti-HRG Antibody

Target: HRG (Histidine-Rich Glycoprotein (HRG))

Binding Specificity: AA 412-511

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HRG antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Cross-Reactivity: Human

Purification: >95%, Protein G purified

Immunogen: Recombinant Human Histidine-rich glycoprotein protein (412-511AA)

Isotype: IgG

Application Details

Application Notes: Recommended dilution: WB:1:500-1:5000, IHC:1:200-1:500,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for HRG

Target: HRG (Histidine-Rich Glycoprotein (HRG))

Alternative Name: HRG (HRG Products)

Synonyms: AI265597 antibody, AW413091 antibody, D16jh2 antibody, D18020 antibody, Hprg antibody, Hrgp antibody, HPRG antibody, HRGP antibody, THPH11 antibody, HRG1 antibody, histidine rich glycoprotein antibody, histidine-rich glycoprotein antibody, HRG antibody, LOAG_12427 antibody, LOC100597044 antibody, Hrg antibody

Background:

Background: Plasma glycoprotein that binds a number of ligands such as heme, heparin, heparan sulfate, thrombospondin, plasminogen, and divalent metal ions. Binds heparin and heparin/glycosaminoglycans in a zinc-dependent manner. Binds heparan sulfate on the surface of liver, lung, kidney and heart endothelial cells. Binds to N-sulfated polysaccharide chains on the surface of liver endothelial cells. Inhibits rosette formation. Acts as an adapter protein and is implicated in regulating many processes such as immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis. Mediates clearance of necrotic cells through enhancing the phagocytosis of necrotic cells in a heparan sulfate-dependent pathway. This process can be regulated by the presence of certain HRG ligands such as heparin and zinc ions. Binds to IgG subclasses of immunoglobins containing kappa and lambda light chains with different affinities regulating their clearance and inhibiting the formation of insoluble immune complexes. Tethers plasminogen to the cell surface. Binds T-cells and alters the cell morphology. Modulates angiogenesis by blocking the CD6-mediated antiangiongenic effect of thrombospondins, THBS1 and THBS2. Acts as a regulator of the vascular endothelial growth factor (VEGF) signaling pathway, inhibits endothelial cell motility by reducing VEGF-induced complex formation between PXN/paxillin and ILK/integrin-linked protein kinase and by promoting inhibition of VEGF-induced tyrosine phosphorylation of focal adhesion kinases and alpha-actinins in endothelial cells. Also plays a role in the regulation of tumor angiogenesis and tumor immune surveillance. Normalizes tumor vessels and promotes antitumor immunity by polarizing tumor-associated macrophages, leading to decreased tumor growth and metastasis.

Aliases: HRG antibody, Histidine-rich glycoprotein antibody, Histidine-proline-rich glycoprotein antibody, HPRG antibody

UniProt: P04196